Price of AP-26113
please inquire via email@example.com
or Fax: 1-201-884-1288
We match the lowest price on market.
Related ALK Inhibitors
AP-26113 is a novel orally available, and potent dual kinase inhibitor of ALK and EGFR.
AP26113 is an anaplastic lymphoma kinase (ALK) inhibitor. It is designed to overcome resistance mutations in ALK, specificially the ALK-L1196M mutation that results in resistance to another ALK inhibitor, crizotinib (PFE).
AP26113 also inhibits activated EGFR in preclinical models, including the T790M "gatekeeper" mutant that confers resistance to current EGFR inhibitors. Constitutive EGFR activity due to activating mutation is a key feature of certain non-small cell lung cancers, and the T790M mutation causes resistance to inhibitor therapy in approximately 50 percent of these cases. AP26113 has shown to be specific for mutated EGFR and avoids inhibition of native (endogenous or unmutated) EGFR; such inhibition is thought to be associated with the toxicity of other EGFR inhibitors.
Chemical Formula: C29H39ClN7O2P
Storage Conditions: 2ºC to 8 ºC, or -20ºC for 2 years.